To answer your question, yes, I would have stuck a

To answer your question, yes, I would have stuck around. But you will be surprised as to why I say yes.

I listened to you and bought SCRC almost two years ago because of RapiMeds, and never regretted it. In February Bob introduced compounding to the SCRC investors and in eleven months this revenue source has proven to be a outstanding success as we all know - bringing Scrips to a $60M+ annual run rate. But, in his radio interview several months ago he stated RapiMeds will surpass compounding. This has been an exciting ride and I truly believe it hasn't even started yet. Bob has never given on RapiMeds and neither have I. On every occasion Bob has had to speak out in the past couple months he has spoken about RapiMeds with a high level of excitement and enthusiasm for what it will mean to the investors in the long term. The potential, not only for the pediatric RapiMeds but the RapiMeds technology applied to other medical conditions, cannot be calculated. The Hong Kong/China OTC market is massive. I compare the launch of RapiMeds in the Asian market to throwing a little lit match into an ocean of gasoline.

So yes, I would have stuck around but not because of compounding, but because I feel compounding will be the icing on the cake to RapiMeds huge success.

And lastly, I believe it will be an early Christmas for all SCRC Investors.